Notes: Lusutrombopag is an agonist of the thrombopoietin receptor.{45125} It induces proliferation of Ba/F3 cells expressing human MPL, the gene for the thrombopoietin receptor, with an EC50 value of 84 nM but not of those expressing mouse Mpl.{45126} Lusutrombopag (0.3-10 mg/kg per day) increases the number of circulating platelets in a transgenic mouse model expressing human MPL and increases the number of megakaryocytes in the bone marrow when administered at a dose of 10 mg/kg per day. Formulations containing lusutrombopag have been used in the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo invasive procedures.